No profile data available.
Immuneering Corporation (IMRX) is a healthcare company in the additional cancer treatment drugs industry, based in Cambridge, United States, with about 57 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$56.02 million. Its market capitalization was $254.91 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States.
Immuneering reported $0 in revenue for fiscal year 2025.
$254.91 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Northwest Biotherapeutics, Inc. (NWBO), Fate Therapeutics, Inc. (FATE), Zentalis Pharmaceuticals, Inc. (ZNTL), Pyxis Oncology, Inc. (PYXS).